ACHE and Alzheimer disease: Current AD therapies can only temporarily improve learning and memory by maintaining the levels of ACh and cholinergic transmission by AChE inhibitors or regulating glutamatergic transmission by blockers of N-methyl-d-aspartate (NMDA) receptors.